{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=17", "query": { "condition": "Advanced Solid Tumour", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 3366, "total_pages": 337, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T11:33:38.565Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01629758", "title": "Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms by Site" ], "interventions": [ { "name": "Denenicokin", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2012-06", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-03-06", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01629758" }, { "nct_id": "NCT01332604", "title": "GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers" ], "interventions": [ { "name": "GDC-0980", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2011-07", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 3, "location_summary": "Los Angeles, California • Aurora, Colorado • Rochester, Minnesota", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332604" }, { "nct_id": "NCT06630247", "title": "A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers", "Solid Tumor Cancer", "Solid Tumor Malignancy", "Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)", "Metastatic Solid Tumor", "Locally Advanced Solid Tumor", "Urothelial Cancer of Renal Pelvis" ], "interventions": [ { "name": "XL495", "type": "DRUG" }, { "name": "ADC cytotoxic agents", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2024-10-17", "completion_date": "2025-05-07", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 10, "location_summary": "Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jefferson", "state": "Louisiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630247" }, { "nct_id": "NCT00021047", "title": "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Portsmouth, Virginia", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Portsmouth", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021047" }, { "nct_id": "NCT07226349", "title": "A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BG-75098", "type": "DRUG" }, { "name": "BGB-43395", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2025-12-11", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Duarte, California • New Haven, Connecticut + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226349" }, { "nct_id": "NCT05791448", "title": "AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cholangiocarcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Neoplasm in the Liver", "Refractory Malignant Solid Neoplasm", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "RNA Transcription Modulator AU-409", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-03-29", "completion_date": "2028-03-29", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05791448" }, { "nct_id": "NCT00003706", "title": "LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "1998-04", "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2012-06-28", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003706" }, { "nct_id": "NCT01439152", "title": "Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Oncology" ], "interventions": [ { "name": "BAY94-9343", "type": "DRUG" }, { "name": "BAY94-9343 (Expansion)", "type": "DRUG" }, { "name": "BAY94-9343 (1.8 mg/kg)", "type": "DRUG" }, { "name": "BAY94-9343 (2.2 mg/kg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2011-09-07", "completion_date": "2019-07-30", "has_results": false, "last_update_posted_date": "2021-07-09", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 8, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Bethesda, Maryland + 5 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01439152" }, { "nct_id": "NCT06581432", "title": "Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "Zongertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 588, "start_date": "2024-10-11", "completion_date": "2028-12-29", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 20, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 16 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06581432" }, { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-15T11:33:38.565Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" } ] }